* AVROBIO Inc AVRO.OQ AVRO.O is expected to show no
change in
quarterly revenue when it reports results on August 7
(estimated).
*
* Refinitiv's mean analyst estimate for AVROBIO Inc is for
a loss
of 7 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for AVROBIO Inc
is
$4, above its last closing price of $1.52.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.54 -0.54 -0.57 Missed -4.6
Dec. 31 2023 -0.49 -0.57 Missed -15.7
Sep. 30 2022 -0.57 -0.55 -0.52 Beat 5.5
Jun. 30 2022 -0.59 -0.57 -0.64 Missed -11.8
Mar. -0.58 -0.59 -0.68 Missed -14.8
31 2022
Dec. 31 2021 -0.71 -0.74 -0.65 Beat 12.2
Sep. 30 2021 -0.75 -0.76 -0.75 Beat 1
Jun. 30 2021 -0.66 -0.67 -0.74 Missed -10.3
This summary was machine generated August 4 at 18:34 GMT. All
figures in US dollars unless otherwise stated